Page 146 - Genentech News Today

Every year, over 600,000 women worldwide are diagnosed with cervical cancer and over 340,000 die from this preventable disease, caused by infection with human papillomavirus (HPV). Nine out of 10 women

The MERIT trial of intravitreal dexamethasone, ranibizumab, or methotrexate for persistent or recurrent macular edema after uveitis treatment found that only dexamethasone improved vision.

Repeat treatment with corticosteroid injections improved vision in people with persistent or recurrent uveitis-related macular edema better than two other therapies, according to results from a clinical trial funded by the National Eye Institute.

On June 15, 1953, the San Mateo County Development Association was officially incorporated by the state of California. The word “Economic” would not enter its name until later. Most people

Pharmacists should learn the basics of this leading cause of vision loss among adults worldwide.

It is unclear whether adding venetoclax to treatment with ibrutinib and obinutuzumab can improve outcomes in older CLL patients.

CHICAGO — Mirvetuximab soravtansine-gynx extended survival of women with platinum-resistant ovarian cancer and high folate receptor-alpha expression, according to a study that compared the agent with investigator’s choice of chemotherapy.The antibody and microtubule inhibitor conjugate is the first novel therapy to show a survival benefit in a randomized phase 3 study among this

CHICAGO — The addition of tumor-treating fields to second-line therapy prolonged survival for patients with metastatic non-small cell lung cancer whose disease progressed on or after platinum therapy, according to results presented at ASCO Annual Meeting. Researchers observed no exacerbation in systemic toxicities and reported few high-grade device-related toxicities, results of the

In a 6-month trial, more than 85% of adults on CBD showed significant reduction in the number of monthly seizures, suggesting this treatment may be an effective adjuvant option.

Data from two studies continue to show the long-term efficacy and safety of fixed-duration venetoclax combination regimens across different lines of therapy in...